80 related articles for article (PubMed ID: 26463635)
21. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
Xu-Monette ZY; Zhou J; Young KH
Blood; 2018 Jan; 131(1):68-83. PubMed ID: 29118007
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of immunohistochemical subtypes in diffuse large B-cell lymphoma and its impact on survival.
Dwivedi A; Mehta A; Solanki P
Indian J Pathol Microbiol; 2015; 58(4):453-8. PubMed ID: 26549066
[TBL] [Abstract][Full Text] [Related]
23. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Xu-Monette ZY; Dabaja BS; Wang X; Tu M; Manyam GC; Tzankov A; Xia Y; Zhang L; Sun R; Visco C; Dybkaer K; Yin L; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Zhao X; Winter JN; Piris MA; McDonnell TJ; Miranda RN; Li Y; Medeiros LJ; Young KH
Mod Pathol; 2015 Dec; 28(12):1555-73. PubMed ID: 26541272
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic Heterogeneity of B-Cell Lymphoma: Chromatin Modifiers.
Hopp L; Nersisyan L; Löffler-Wirth H; Arakelyan A; Binder H
Genes (Basel); 2015 Oct; 6(4):1076-112. PubMed ID: 26506391
[TBL] [Abstract][Full Text] [Related]
25. P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma.
Vega GG; Avilés-Salas A; Chalapud JR; Martinez-Paniagua M; Pelayo R; Mayani H; Hernandez-Pando R; Martinez-Maza O; Huerta-Yepez S; Bonavida B; Vega MI
BMC Cancer; 2015 Oct; 15():722. PubMed ID: 26475474
[TBL] [Abstract][Full Text] [Related]
26. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.
Klanova M; Andera L; Brazina J; Svadlenka J; Benesova S; Soukup J; Prukova D; Vejmelkova D; Jaksa R; Helman K; Vockova P; Lateckova L; Molinsky J; Maswabi BC; Alam M; Kodet R; Pytlik R; Trneny M; Klener P
Clin Cancer Res; 2016 Mar; 22(5):1138-49. PubMed ID: 26467384
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
[TBL] [Abstract][Full Text] [Related]
28. The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma.
Chen BJ; Dashnamoorthy R; Galera P; Makarenko V; Chang H; Ghosh S; Evens AM
Oncotarget; 2019 Mar; 10(21):2030-2040. PubMed ID: 31007846
[TBL] [Abstract][Full Text] [Related]
29. [Expression of PD-1, TIM-3, LAG-3 and BTLA in diffuse large B-cell lymphoma and its effect on prognosis].
Liu XY; Yuan XL; Ma RJ; Xu H; Yang SW; Nie L; Zhang L; Hu AX; Li Z; Zhu ZM
Zhonghua Yi Xue Za Zhi; 2020 Sep; 100(36):2846-2853. PubMed ID: 32988145
[No Abstract] [Full Text] [Related]
30. Single-Cell RNA-Seq and Bulk RNA-Seq Reveal Intratumoral Heterogeneity and Tumor Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma.
Zhao Y; Xu H; Zhang M; Li L
Front Genet; 2022; 13():881345. PubMed ID: 35601491
[No Abstract] [Full Text] [Related]
31. Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL).
Zhang W; Fan Y; Li M; Yang L; Zhang Z; Liu L
Dis Markers; 2021; 2021():4894022. PubMed ID: 34567285
[TBL] [Abstract][Full Text] [Related]
32. Distinct Molecular Subtypes of Diffuse Large B Cell Lymphoma Patients Treated with Rituximab-CHOP Are Associated with Different Clinical Outcomes and Molecular Mechanisms.
Yu H; Peng S; Han S; Chen X; Lyu Q; Lei T
Biomed Res Int; 2021; 2021():5514726. PubMed ID: 34250086
[TBL] [Abstract][Full Text] [Related]
33. Flow Cytometry-Assessed PD1/PDL1 Status in Tumor-Infiltrating Lymphocytes: A Link With the Prognosis of Diffuse Large B-Cell Lymphoma.
Chen Z; Deng X; Ye Y; Zhang W; Liu W; Zhao S
Front Oncol; 2021; 11():687911. PubMed ID: 34211855
[TBL] [Abstract][Full Text] [Related]
34. Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial.
Jiménez-Cortegana C; Palazón-Carrión N; Martin Garcia-Sancho A; Nogales-Fernandez E; Carnicero-González F; Ríos-Herranz E; de la Cruz-Vicente F; Rodríguez-García G; Fernández-Álvarez R; Rueda Dominguez A; Casanova-Espinosa M; Martínez-Banaclocha N; Gumà-Padrò J; Gómez-Codina J; Labrador J; Salar-Silvestre A; Rodriguez-Abreu D; Galvez-Carvajal L; Provencio M; Sánchez-Beato M; Guirado-Risueño M; Espejo-García P; Lejeune M; Álvaro T; Sánchez-Margalet V; de la Cruz-Merino L; ; ;
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34158317
[TBL] [Abstract][Full Text] [Related]
35. Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma.
Csizmar CM; Ansell SM
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33804869
[TBL] [Abstract][Full Text] [Related]
36. Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade.
Roussel M; Le KS; Granier C; Llamas Gutierrez F; Foucher E; Le Gallou S; Pangault C; Xerri L; Launay V; Lamy T; Tartour E; Olive D; Fest T
Blood Adv; 2021 Apr; 5(7):1816-1829. PubMed ID: 33787861
[TBL] [Abstract][Full Text] [Related]
37. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4
Roessner PM; Llaó Cid L; Lupar E; Roider T; Bordas M; Schifflers C; Arseni L; Gaupel AC; Kilpert F; Krötschel M; Arnold SJ; Sellner L; Colomer D; Stilgenbauer S; Dietrich S; Lichter P; Izcue A; Seiffert M
Leukemia; 2021 Aug; 35(8):2311-2324. PubMed ID: 33526861
[TBL] [Abstract][Full Text] [Related]
38. Immune-Checkpoint Inhibitors in B-Cell Lymphoma.
Armengol M; Santos JC; Fernández-Serrano M; Profitós-Pelejà N; Ribeiro ML; Roué G
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33430146
[TBL] [Abstract][Full Text] [Related]
39. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma.
van Bruggen JAC; Martens AWJ; Tonino SH; Kater AP
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33353234
[TBL] [Abstract][Full Text] [Related]
40. The effect of PD-1 expression on tumor-associated macrophage in T cell lymphoma.
Ruan J; Ouyang M; Zhang W; Luo Y; Zhou D
Clin Transl Oncol; 2021 Jun; 23(6):1134-1141. PubMed ID: 33211280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]